C

Caribou Biosciences

142 employees

Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.

Investor insights

Sectors invested in

Medical1

Health Care1

Therapeutics1

Genetics1

Biotechnology1

Funding rounds participated in

$15M sweet spot round size

Most of their 1 investments are in rounds between $15M and $15M

Basic info

Industry

biotechnology research

Sectors

Biotechnology

allogeneic CAR-T cell therapies

Health Care

Therapeutics

Next-generation CRISPR genome editing

iPSC-derived NK cell therapies

oncology

Date founded

2011

Investments made

I

Intellia Therapeutics, Inc. raised $15M on November 18, 2014

Investors: Atlas Venture and Caribou Biosciences

Funding rounds raised

Total raised

$115M

from 20 investors over 20 rounds

C

Caribou Biosciences raised $115M on March 3, 2021

Investors: Maverick Ventures, Partner Fund Management, Monashee Investment Management LLC, Tekla Capital Management, The Leukemia & Lymphoma Society, Point72 Ventures, LifeSci Venture Partners, Ridgeback Capital Management LLC and Mission BioCapital

C

Caribou Biosciences raised undisclosed on May 16, 2016

Investors: Mission Bay Capital, Maverick Ventures, Anterra Capital, F-Prime Capital Partners, Aliment Capital and Genoa Ventures

C

Caribou Biosciences raised $11M on March 25, 2015

Investors: Mission Bay Capital, Howard Hughes Medical Institute, Genoa Ventures and F-Prime Capital Partners

C

Caribou Biosciences raised $12M on September 22, 2014

Investors: Employee Stock Option Fund (ESO Fund)